¼¼°èÀÇ ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ : ÀûÀÀÁõº°, Á¦Ç°º°, Áö¿ªº°(2024-2032³â)
Genitourinary Drugs Market Report by Indication, Product, and Region 2024-2032
»óǰÄÚµå : 1540918
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 142 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â 332¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC ±×·ìÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 396¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2024-2032³â°£ 1.9%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ºñ´¢»ý½Ä±â°è´Â ½ÅÀå, ¿ä°ü, ¹æ±¤, ¿äµµ, »ý½Ä±â µîÀ» Æ÷ÇÔÇÏ¸ç »ý½Ä ¹× ü³» ³ëÆó¹° ¹èÃâ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±× ±â´ÉÀº ¼±Ãµ¼º ±âÇü, ÀÌÁúÀû ¼Õ»ó, ¾Ï, ¿Ü»ó, °¨¿°, ¼ö´¢Áõ, ¿°Áõ µîÀÇ ¿øÀÎÀ¸·Î ÀÎÇØ ¾ïÁ¦µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´À¸·Î °íÅë¹Þ´Â ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºñ´¢»ý½Ä±â Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºñ´¢»ý½Ä±â Ä¡·á´Â »ý½Ä±â°ü, ¹è¼³°è, ¿ä·Î°è ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ¹æ±¤ °æ·Ã, ¹ß±âºÎÀü Ä¡·á, Á¶»ê ¿¹¹æÀ» À§ÇÑ Àڱà ¼öÃà ¾ïÁ¦¿¡µµ »ç¿ëµË´Ï´Ù.

ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ½ÃÀå µ¿Çâ :

ºñ´¢»ý½Ä±â ÁúȯÀÇ À§Çè Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ºñ´¢»ý½Ä±â Ä¡·á´Â ¸¸¼º ½ÅºÎÀü ¹× ¿ä·Î °¨¿°À» ¾Î°í ÀÖ´Â ¼Ò¾Æ ȯÀÚ Ä¡·á¿¡ È¿°úÀûÀ̱⠶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ¸ÅÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ½ÃÀåÀ» ¼±µµÇÏ´Â ±â¾÷µéÀº ±âÁ¸ È­Çпä¹ýÁ¦ ¹× È£¸£¸ó ¿ä¹ý¿¡ ³»¼ºÀ» ȹµæÇÑ ¸¸¼º Àü¸³¼±¾Ï ȯÀÚ Ä¡·á¿¡ µµ¿òÀÌ µÇ´Â ¾à¹°À» µµÀÔÇϱâ À§ÇØ Á¦Çü ±â¼ú ¹ßÀü¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠ´Ù±¹Àû ±â¾÷(MNC)Àº Â÷¼¼´ë Ä¡·áÁ¦¸¦ Ãâ½ÃÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ¹ÙÀÌ¿À ÀǾàǰ ¸®´õµé°ú Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Èıâ ÀÓ»ó ´Ü°è¿¡ ÀÖ´Â ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰÀÇ ¼ö°¡ Å©°Ô Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¢±¹ÀÇ Á¤ºÎ ¹× ºñÁ¤ºÎ ±â°üÀÌ ÈÄ¿øÇÏ´Â ¿¬±¸ °³¹ß(R&D) ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±µµ ÇâÈÄ ¸î ³â°£ ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ºñ´¢»ý½Ä±â Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦9Àå SWOT ºÐ¼®

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå PorterÀÇ Five Forces ºÐ¼®

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global genitourinary drugs market size reached US$ 33.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.6 Billion by 2032, exhibiting a growth rate (CAGR) of 1.9% during 2024-2032.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:

The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication and product.

Breakup by Indication:

Prostate Cancer

Ovarian Cancer

Bladder Cancer

Cervical Cancer

Renal Cancer

Erectile Dysfunction

Urinary Tract Infections

Urinary Incontinence and Overactive Bladder

Sexually Transmitted Diseases

Interstitial Cystitis

Hematuria

Benign Prostatic Hyperplasia

Breakup by Product:

Urological

Hormonal Therapy

Gynecological

Anti-infectives

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Genitourinary Drugs Market

6 Market Breakup by Indication

7 Market Breakup by Product

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â